MFP
OBIO icon

Meramec Financial Planners’s Orchestra BioMed OBIO Stock Holding History

Meramec Financial Planners’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115K Hold
30,000
– – 0.04% 166
2026
Q1 		$131K Hold
30,000
– – 0.05% 141
2025
Q4 		$117K Buy
+30,000
New +$121K 0.05% 157

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Meramec Financial Planners's OBIO Position: Q2 2026 in Review

Meramec Financial Planners held its Orchestra BioMed (OBIO) position steady in Q2 2026 at 30,000 shares worth $115K. The position accounts for 0.04% of the portfolio, ranked #166.

Meramec Financial Planners first reported a position in OBIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $131K in Q1 2026. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Meramec Financial Planners held 30,000 shares of Orchestra BioMed worth $115K as of Q2 2026.
  • Meramec Financial Planners left its Orchestra BioMed share count unchanged in Q2 2026.
  • Orchestra BioMed made up 0.04% of Meramec Financial Planners's portfolio in Q2 2026, its #166 holding.
  • Meramec Financial Planners first reported a position in Orchestra BioMed in Q4 2025 and has held it in 3 quarters since.
  • Meramec Financial Planners's Orchestra BioMed position peaked at $131K in Q1 2026.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Meramec Financial Planners's 13F filing for Q2 2026, filed 29 Jul 2026.